Abstract

Otto Warburg described tumour cells as displaying enhanced aerobic glycolysis whilst maintaining defective oxidative phosphorylation (OXPHOS) for energy production almost 100 years ago [1, 2]. Since then, the ‘Warburg effect’ has been widely accepted as a key feature of rapidly proliferating cancer cells [3–5]. What is not clear is how early “Warburg metabolism” initiates in cancer and whether changes in energy metabolism might influence tumour progression ab initio. We set out to investigate energy metabolism in the HRASG12V driven preneoplastic cell (PNC) at inception, in a zebrafish skin PNC model. We find that, within 24 h of HRASG12V induction, PNCs upregulate glycolysis and blocking glycolysis reduces PNC proliferation, whilst increasing available glucose enhances PNC proliferation and reduces apoptosis. Impaired OXPHOS accompanies enhanced glycolysis in PNCs, and a mild complex I inhibitor, metformin, selectively suppresses expansion of PNCs. Enhanced mitochondrial fragmentation might be underlining impaired OXPHOS and blocking mitochondrial fragmentation triggers PNC apoptosis. Our data indicate that altered energy metabolism is one of the earliest events upon oncogene activation in somatic cells, which allows a targeted and effective PNC elimination.

Details

Title
Preneoplastic cells switch to Warburg metabolism from their inception exposing multiple vulnerabilities for targeted elimination
Author
Myllymäki, Henna 1 ; Kelly, Lisa 2 ; Elliot, Abigail M. 3 ; Carter, Roderick N. 4 ; Johansson, Jeanette Astorga 2   VIAFID ORCID Logo  ; Chang, Kai Yee 2 ; Cholewa-Waclaw, Justyna 5 ; Morton, Nicholas M. 6 ; Feng, Yi 7   VIAFID ORCID Logo 

 The University of Edinburgh, Centre for Inflammation Research, Institute for Regeneration and Repair, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); Fimlab Laboratoriot Oy Ltd, Tampere, Finland (GRID:grid.511163.1) (ISNI:0000 0004 0518 4910) 
 The University of Edinburgh, Centre for Inflammation Research, Institute for Regeneration and Repair, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
 The University of Edinburgh, Centre for Inflammation Research, Institute for Regeneration and Repair, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); Garscube Estate, Cancer Research UK Scotland Institute, Glasgow, UK (GRID:grid.4305.2) 
 University of Edinburgh, Queen’s Medical Research Institute, University/British Heart Foundation Centre for Cardiovascular Science, Edinburgh, UK (GRID:grid.511172.1) (ISNI:0000 0004 0613 128X) 
 The University of Edinburgh, High Content Screening Facility, Institute for Regeneration and Repair, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
 University of Edinburgh, Queen’s Medical Research Institute, University/British Heart Foundation Centre for Cardiovascular Science, Edinburgh, UK (GRID:grid.511172.1) (ISNI:0000 0004 0613 128X); Nottingham Trent University, Centre for Systems Health and Integrated Metabolic Research, Department of Biosciences, School of Science and Technology, Nottingham, UK (GRID:grid.12361.37) (ISNI:0000 0001 0727 0669) 
 The University of Edinburgh, Centre for Inflammation Research, Institute for Regeneration and Repair, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); University of Edinburgh, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
Pages
7
Publication year
2024
Publication date
Dec 2024
Publisher
Nature Publishing Group
e-ISSN
21579024
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2918400412
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.